Get the Stockscreener App
40.46
4.82%
-2.05
After Hours:
40.39
-0.07
-0.17%
First Tracks Biotherapeutics Inc stock is traded at $40.46, with a volume of 456.22K.
It is down -4.82% in the last 24 hours and down -12.06% over the past month.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
See More
Previous Close:
$42.51
Open:
$41.06
24h Volume:
456.22K
Relative Volume:
0.63
Market Cap:
$1.45B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.34%
1M Performance:
-12.06%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$40.38
$42.00
1-Week Range:
$39.83
$47.98
52-Week Range:
$14.72
$49.91
First Tracks Biotherapeutics Inc Stock (TRAX) Company Profile
Name
First Tracks Biotherapeutics Inc
Sector
Industry
Phone
212-373-3000
Address
10770 WATERIDGE CIRCLE, SAN DIEGO
Compare TRAX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAX
First Tracks Biotherapeutics Inc
|
40.46 | 1.50B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
First Tracks Biotherapeutics Inc Stock (TRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | Leerink Partners | Outperform |
| Apr-24-26 | Initiated | Wedbush | Outperform |
| Apr-23-26 | Initiated | JP Morgan | Overweight |
| Apr-22-26 | Initiated | Barclays | Overweight |
| Apr-21-26 | Initiated | UBS | Buy |
First Tracks Biotherapeutics Inc Stock (TRAX) Latest News
J.P. Morgan Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $65 - Moomoo
Piper Sandler Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $95 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
First Tracks Biotherapeutics CBO Benjamin Stone Receives 60,492 Performance Stock Units - Kalkine Media
First Tracks Biotherapeutics' CMO Paul F. Lizzul Earns 60,492 Performance Stock Units Following Certified Milestones - Kalkine Media
First Tracks Biotherapeutics CEO Daniel Faga Awarded 193,575 Performance Stock Units - Kalkine Media
First Tracks (TRAX) insider records new share trades - Stock Titan
First Tracks Biotherapeutics (TRAX) insider updates holdings - Stock Titan
First Tracks Biotherapeutics (TRAX) insider logs trades - Stock Titan
Wolfe Research Begins Coverage on First Tracks Biotherapeutics (NASDAQ:TRAX) - MarketBeat
Wolfe Research initiates First Tracks stock with outperform rating By Investing.com - Investing.com Canada
We're Hopeful That First Tracks Biotherapeutics (NASDAQ:TRAX) Will Use Its Cash Wisely - Sahm
FIRST TRACKS BIOTHERAPEUTICS INC : JP MORGAN RAISES TARGET PRICE TO $65 FROM $30 - Bitget
Why Did CRCL Stock Lose Steam? Wall Street Split On Circle’s Banking Win - Stocktwits
AnaptysBio earnings ahead: First results as royalty company By Investing.com - Investing.com Australia
AnaptysBio earnings ahead: First results as royalty company - Investing.com
TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
TRAX SEC FilingsFirst Tracks Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
First Tracks Biotherapeutics (NASDAQ: TRAX) Share Price, TRAX Stock News, TRAX Share Price & Updates - kalkine.ca
First Tracks Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $63.38, Implies 37% Upside - TradingView
Piper Sandler raises First Tracks stock price target on pipeline progress - Investing.com Australia
TRAX Maintained by First Tracks -- Price Target Raised to $95.00 - GuruFocus
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results - Benzinga
A Quick Look at Today's Ratings for First Tracks Biotherapeutics(TRAX.US), With a Forecast Between $57 to $95 - Moomoo
TRAX Maintained by HC Wainwright & Co. -- Price Target Raised to $57.00 - GuruFocus
Wedbush Adjusts PT on First Tracks Biotherapeutics to $70 From $60, Maintains Outperform Rating - marketscreener.com
First Tracks Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $60.5, Implies 31% Upside - tradingview.com
Barclays Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $65 - Moomoo
TRAX SWOT Analysis: Clinical Pipeline and Financial Challenges R - GuruFocus
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:13 AM - Bitget
First Tracks Biotherapeutics Reports Q2 2026 Financial Results Following Spin-Off - Kalkine Media
Form 8K FIRST TRACKS BIOTHERAPEUTICS For: 12 August By Investing.com - Investing.com South Africa
First Tracks Biotherapeutics 2Q 2026: Net loss $(33.4M), EPS $(0.95) — 10-Q Summary - TradingView
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
First Tracks Biotherapeutics (TRAX) details $83.9M loss and $168M cash after spin-off - Stock Titan
FMR LLC Acquires Stake in First Tracks Biotherapeutics Inc (TRAX): A Strategic Bet on Clinical-Stage Innovation - GuruFocus
UBS Initiates First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Announces Target Price $65 - Moomoo
UBS Adjusts First Tracks Biotherapeutics PT to $65 From $45, Maintains Buy Rating - Moomoo
First Tracks Biotherapeutics (TRAX) reports 16,667 performance stock units - Stock Titan
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? - Investing.com
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? By Investing.com - Investing.com Canada
First Tracks Biotherapeutics Ord Shs (TRAX) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
First Tracks Biotherapeutics (TRAX) awards 60,492 performance stock units - Stock Titan
First Tracks Biotherapeutics (TRAX) awards 60,492 PSUs to CMO - Stock Titan
Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR - RTTNews
First Tracks Biotherapeutics Inc (TRAX) Gets a Buy from Wells Fargo - The Globe and Mail
Wells Fargo Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Wells Fargo Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $55 - Moomoo
First Tracks Biotherapeutics: Buy Rating Reaffirmed with Unchanged $44 Price Target on ANB033 CD122-Targeting Upside and Acquisition Potential - TipRanks
After Forte acquisition, H.C. Wainwright says First Tracks could be target - TipRanks
TRAX Stock Volatile As Traders Focus On Cash And Momentum - StocksToTrade
First Tracks Biotherapeutics Inc Stock (TRAX) Financials Data
There is no financial data for First Tracks Biotherapeutics Inc (TRAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
First Tracks Biotherapeutics Inc Stock (TRAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jain Rita | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
7,330 |
0 |
19,194 |
| Schmid John P. | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
37,652 |
| Orwin John A | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
16,695 |
| Ware J. Anthony | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
15,660 |
| Marquet Magda | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
15,960 |
| FENTON DENNIS M | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
10,995 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):